Lantheus Completes Acquisition of Life Molecular Imaging, Appoints Ludger Dinkelborg as Head of R&D.

Lantheus Holdings has completed its acquisition of Life Molecular Imaging, a subsidiary of Life Healthcare Group Holdings. Ludger Dinkelborg, former CEO of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus. The acquisition is expected to expand Lantheus' product portfolio and capabilities.

Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical-focused company, has successfully completed its acquisition of Life Molecular Imaging Ltd. (Life Molecular), a subsidiary of Life Healthcare Group Holdings Ltd. The acquisition, announced on July 22, 2025, includes the appointment of Ludger Dinkelborg, PhD, former CEO of Life Molecular Imaging, as Head of Research and Development at Lantheus, effective August 1, 2025 [1].

As part of the acquisition, Lantheus gains Neuraceq® (florbetaben F18 injection), a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s disease. The transaction also provides Lantheus with a robust Alzheimer’s disease radiodiagnostic commercial infrastructure, advanced R&D capabilities, and an established international footprint [1].

In his new role, Dr. Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions, reporting directly to the CEO, Brian Markison. "This is a pivotal moment for Lantheus, and I’m honored to help shape the next chapter," said Dr. Dinkelborg [1].

The acquisition aligns with Lantheus' strategic expansion efforts to enhance its radiopharmaceutical leadership and sustain long-term growth. The company has also announced plans to divest its SPECT business to SHINE Technologies, streamlining operations and focusing on PET radiodiagnostics and radiotherapeutic agents [2].

The acquisition is expected to expand Lantheus' product portfolio and capabilities, particularly in the Alzheimer's radiodiagnostic market, which has a potential total addressable market of $1.5 billion by the end of the decade [2].

Wall Street analysts forecast an average target price of $127.85 for Lantheus Holdings Inc (LNTH), with a high estimate of $159.00 and a low estimate of $109.00, implying an average upside of 78.66% from the current price of $71.56 [2].

References:
[1] https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-completes-acquisition-life-molecular-imaging-and
[2] https://www.gurufocus.com/news/2992891/lantheus-holdings-lnth-completes-acquisition-of-life-molecular-imaging-lnth-stock-news